Quest Diagnostics (NYSE:DGX) & Daxor (NASDAQ:DXR) Head-To-Head Review

Quest Diagnostics (NYSE:DGX) and Daxor (NASDAQ:DXR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Quest Diagnostics and Daxor, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0	10	7	0	2.41
Daxor	0	1	1	0	2.50

Quest Diagnostics currently has a consensus price target of $197.27, indicating a potential upside of 9.40%. Daxor has a consensus price target of $25.00, indicating a potential upside of 82.75%. Given Daxor’s stronger consensus rating and higher probable upside, analysts clearly believe Daxor is more favorable than Quest Diagnostics.

Valuation and Earnings

This table compares Quest Diagnostics and Daxor”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$9.87 billion	2.03	$871.00 million	$8.52	21.16
Daxor	N/A	N/A	N/A	N/A	N/A

Quest Diagnostics has higher revenue and earnings than Daxor.

Profitability

This table compares Quest Diagnostics and Daxor’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	8.91%	15.47%	6.84%
Daxor	N/A	N/A	N/A

Insider and Institutional Ownership

88.1% of Quest Diagnostics shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 8.2% of Quest Diagnostics shares are held by company insiders. Comparatively, 59.5% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Quest Diagnostics beats Daxor on 6 of the 9 factors compared between the two stocks.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.